FR3119539B1 - Therapeutic composition inhibiting DHODH - Google Patents
Therapeutic composition inhibiting DHODH Download PDFInfo
- Publication number
- FR3119539B1 FR3119539B1 FR2101262A FR2101262A FR3119539B1 FR 3119539 B1 FR3119539 B1 FR 3119539B1 FR 2101262 A FR2101262 A FR 2101262A FR 2101262 A FR2101262 A FR 2101262A FR 3119539 B1 FR3119539 B1 FR 3119539B1
- Authority
- FR
- France
- Prior art keywords
- therapeutic composition
- dhodh
- composition inhibiting
- inhibiting dhodh
- neurolaena
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 title 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 title 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241001126925 Lobata Species 0.000 abstract 1
- 241001077880 Neurolaena Species 0.000 abstract 1
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940098465 tincture Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/98—Oxidoreductases acting on the CH-CH group of donors (1.3) with other, known, acceptors (1.3.98)
- C12Y103/98001—Dihydroorotate oxidase (fumarate) (1.3.98.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
[Titre : Composition thérapeutique inhibitrice de la DHODH Composition thérapeutique comprenant une teinture mère d’un extrait de feuilles d’une plante appartenant au genre « Neurolaena » et à l’espèce « lobata » pour utilisation en tant que médicament inhibiteur de la dihydroorotate dehydrogenase humaine (DHODH).][Title: DHODH-inhibiting therapeutic composition Therapeutic composition comprising a mother tincture of an extract of leaves of a plant belonging to the genus “Neurolaena” and the species “lobata” for use as a dihydroorotate dehydrogenase inhibitor drug human (DHODH).]
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2101262A FR3119539B1 (en) | 2021-02-10 | 2021-02-10 | Therapeutic composition inhibiting DHODH |
| FR2200066A FR3119540B1 (en) | 2021-02-10 | 2022-01-05 | DHODH inhibitory therapeutic composition |
| JP2023572055A JP2024507287A (en) | 2021-02-10 | 2022-02-09 | DHODH-inhibiting NEUROLAENA leaf-based therapeutic composition for the treatment of RNA virus infections |
| CA3207366A CA3207366A1 (en) | 2021-02-10 | 2022-02-09 | Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections |
| US18/264,918 US20240123012A1 (en) | 2021-02-10 | 2022-02-09 | Therapeutic composition based on dhodh-inhibiting neurolaena leaves for the treatment of rna virus infections |
| CR20230390A CR20230390A (en) | 2021-02-10 | 2022-02-09 | Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections |
| PCT/EP2022/053144 WO2022171682A1 (en) | 2021-02-10 | 2022-02-09 | Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections |
| EP22702744.8A EP4291217A1 (en) | 2021-02-10 | 2022-02-09 | Therapeutic composition based on dhodh- inhibiting neurolaena leaves for the treatment of rna virus infections |
| CU2023000036A CU20230036A7 (en) | 2021-02-10 | 2022-02-09 | PROCEDURE TO PREPARE A DRY EXTRACT OF A DILUTED MOTHER TINCTURE OF DRIED LEAVES OF NEUROLAENA LOBATA |
| DO2023000157A DOP2023000157A (en) | 2021-02-10 | 2023-08-10 | THERAPEUTIC COMPOSITION BASED ON DHODH INHIBITOR NEUROLAENA LEAVES FOR THE TREATMENT OF INFECTIONS BY RNA VIRUS. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2101262 | 2021-02-10 | ||
| FR2101262A FR3119539B1 (en) | 2021-02-10 | 2021-02-10 | Therapeutic composition inhibiting DHODH |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3119539A1 FR3119539A1 (en) | 2022-08-12 |
| FR3119539B1 true FR3119539B1 (en) | 2023-12-22 |
Family
ID=75278217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2101262A Active FR3119539B1 (en) | 2021-02-10 | 2021-02-10 | Therapeutic composition inhibiting DHODH |
| FR2200066A Active FR3119540B1 (en) | 2021-02-10 | 2022-01-05 | DHODH inhibitory therapeutic composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2200066A Active FR3119540B1 (en) | 2021-02-10 | 2022-01-05 | DHODH inhibitory therapeutic composition |
Country Status (2)
| Country | Link |
|---|---|
| CR (1) | CR20230390A (en) |
| FR (2) | FR3119539B1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999045908A2 (en) * | 1998-03-11 | 1999-09-16 | Ohio State University Research Foundation | Anti-viral uses of leflunomide products |
| US6841561B1 (en) * | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| FR2870457B1 (en) * | 2004-05-19 | 2006-07-14 | Henry Joseph | COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY COOLINGS, AND / OR VIRAL INFECTIONS WITH RNA VIRUSES, AND / OR BY PROTOZOAR PARASITOSES |
-
2021
- 2021-02-10 FR FR2101262A patent/FR3119539B1/en active Active
-
2022
- 2022-01-05 FR FR2200066A patent/FR3119540B1/en active Active
- 2022-02-09 CR CR20230390A patent/CR20230390A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230390A (en) | 2024-01-12 |
| FR3119539A1 (en) | 2022-08-12 |
| FR3119540A1 (en) | 2022-08-12 |
| FR3119540B1 (en) | 2024-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | Chlorogenic acid protects against liver fibrosis in vivo and in vitro through inhibition of oxidative stress | |
| FR2949044B1 (en) | COMPOSITION INCLUDING A FRACTION OF THE UNSAPONIFIABLE | |
| Wang et al. | Resveratrol prevents suppression of regulatory T-cell production, oxidative stress, and inflammation of mice prone or resistant to high-fat diet–induced obesity | |
| Zhang et al. | Deferoxamine inhibits iron-uptake stimulated osteoclast differentiation by suppressing electron transport chain and MAPKs signaling | |
| WO2019199861A3 (en) | Hemp extract for treatment of pain in animals | |
| EP3412292B1 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| DE60330997D1 (en) | BIAROMATIC COMPOUNDS ACTIVATE THE PPAR-GAMMA RECEPTORS AND THEIR APPLICATIONS IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | |
| Akgullu et al. | Nebivolol to attenuate the effects of hyper-homocysteinaemia in rats | |
| Kumari et al. | Promising essential oils/plant extracts in the prevention and treatment of dandruff pathogenesis | |
| BR112014031649A2 (en) | compound represented by formula 1 having activity inhibiting enzyme 11b-hsd1; method for its production and pharmaceutical composition containing the same as active ingredient | |
| FR3119539B1 (en) | Therapeutic composition inhibiting DHODH | |
| Suganuma et al. | Stimulation of phagocytosis by sulforaphane | |
| Popov et al. | Combined therapy of influenza with antiviral drugs with a different mechanism of action in comparison with monotherapy | |
| CN102905699A (en) | Anti-fungal agent | |
| Kido et al. | Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments | |
| MA35398B1 (en) | Novel compounds useful as inhibitors of diacylglycerol acyltransferase | |
| Wang et al. | Two kinds of traditional Chinese medicine prescriptions reduce thymic inflammation levels and improve humoral immunity of finishing pigs | |
| Koppe et al. | The protein-bound uremic toxin p-cresyl-sulfate promotes intracellular ROS production and lipid peroxidation in 3T3-L1 adipose cells | |
| Abaszadeh et al. | Effect of dietary inclusion of atorvastatin, garlic, and dill on growth performance, antioxidant defense, gut, and cardio-pulmonary function, and lipogenesis in broiler chickens | |
| Xiao et al. | Proanthocyanidin A2 attenuates the activation of hepatic stellate cells by activating the PPAR-γ signalling pathway | |
| Guo et al. | Oridonin enhances γ‑globin expression in erythroid precursors from patients with β‑thalassemia via activation of p38 MAPK signaling | |
| Snyder et al. | 13-cis-Retinoic acid specific down-regulation of angiotensin type 1 receptor in rat liver epithelial and aortic smooth muscle cells | |
| Spearow et al. | Improving therapeutics for COVID-19 with glutathione-boosting treatments that improve immune responses and reduce the severity of viral infections | |
| Rajabi et al. | Assessment of N-acetylcysteine as an Alternative for the Treatment of the Premenstrual Dysphoric Disorder: A Randomized Clinical Trial | |
| Jongbloed et al. | Allergies and Natural Alternatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| EXTE | Extension to a french territory |
Extension state: PF |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20220812 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |